MeSH D009157 - myasthenia gravis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cyclosporine | Cyclosporine |  | 2005-03-25 |  |  |
| Cyclophosphamide | Neosar |  | 1993-04-29 |  |  | |
| Padagis | Cyclosporine | Cyclosporine |  | 2003-10-07 |  |  |
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2036-02-15 | 2020-07-30 |  |  |
| Neostigmine | Neostigmine Methylsulfate |  | 2018-07-10 |  |  | |
| Cyclosporine | Cyclosporine |  | 2000-12-20 |  |  | |
| Mylan | Cyclosporine | Cyclosporine |  | 2022-02-02 |  |  |
| Cipla | Cyclophosphamide | Cyclophosphamide |  | 2019-01-18 |  |  |
| Sandoz | Cyclosporine | Cyclosporine |  | 2000-01-13 |  |  |
| Pyridostigmine | Regonol |  | 1982-01-01 |  |  | |
| Cyclophosphamide | Cyclophosphamide |  | 2023-09-12 |  |  | |
| AbbVie | Cyclosporine | Cyclosporine |  | 2000-03-03 |  |  |
| Cyclosporine | Gengraf |  | 2000-05-12 |  |  | |
| Cyclosporine | Restasis Multidose | 2024-08-27 | 2002-12-23 | $224 M | Y2024 | |
| Novartis | Cyclosporine | Neoral |  | 1995-07-14 | $379 M | Q2/19-Q2/22 |
| Cyclosporine | Sandimmune |  | 1983-11-14 |  |  | |
| Bausch Health Companies | Pyridostigmine | Mestinon |  | 1982-01-01 |  |  |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
13%2/15
Phase 2
48%10/21
Phase 3
32%11/34
Approved: 7Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use